{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:15:53Z","timestamp":1763468153520},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.jhep.2013.05.017","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T23:32:29Z","timestamp":1369351949000},"page":"667-674","source":"Crossref","is-referenced-by-count":44,"title":["Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy"],"prefix":"10.1016","volume":"59","author":[{"given":"Eiichi","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakamuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Dohmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeaki","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2013.05.017_b0005","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/hep.510280632","article-title":"Prognosis of chronic hepatitis C: results of a large, prospective cohort study","volume":"28","author":"Niederau","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.05.017_b0010","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1086\/315431","article-title":"A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia","volume":"181","author":"Hayashi","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2013.05.017_b0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jhep.2012.10.017","article-title":"Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study","volume":"58","author":"Ogawa","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.05.017_b0020","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.05.017_b0025","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2013.05.017_b0030","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1440-1746.2008.05319.x","volume":"23","author":"Furusyo","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2013.05.017_b0035","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.05.017_b0040","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.05.017_b0045","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.05.017_b0050","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/hep.24549","article-title":"Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response","volume":"54","author":"Muir","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.05.017_b0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C","volume":"464","author":"Fellay","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2013.05.017_b0060","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1053\/j.gastro.2010.06.071","article-title":"ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy \u2013 a genome-wide study of Japanese HCV virus patients","volume":"139","author":"Ochi","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.05.017_b0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/infdis\/jir210","article-title":"IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C","volume":"204","author":"Chayama","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2013.05.017_b0070","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.05.017_b0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.05.017_b0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-230X-10-38","article-title":"Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment","volume":"10","author":"Ogawa","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2013.05.017_b0085","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/hep.1840190538","article-title":"A proposed system for the nomenclature of hepatitis C viral genotypes","volume":"19","author":"Simmonds","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.05.017_b0090","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1111\/j.1365-2893.2011.01528.x","article-title":"Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C","volume":"19","author":"Hayashi","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2013.05.017_b0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jhep.2013.03.020","article-title":"Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C","volume":"59","author":"Furusyo","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.05.017_b0100","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/j.1440-1746.2011.06965.x","article-title":"Evaluation of the adverse effect of premature discontinuation of pegylated interferon \u03b1-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study","volume":"27","author":"Ogawa","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2013.05.017_b0105","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jhep.2012.04.027","article-title":"Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1","volume":"57","author":"Ogawa","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.05.017_b0110","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jhep.2012.08.003","article-title":"Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial","volume":"57","author":"Furusyo","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.05.017_b0115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00439-002-0798-z","article-title":"Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency","volume":"111","author":"Sumi","year":"2002","journal-title":"Hum Genet"},{"key":"10.1016\/j.jhep.2013.05.017_b0120","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s100380200095","article-title":"DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency","volume":"47","author":"Cao","year":"2002","journal-title":"J Hum Genet"},{"key":"10.1016\/j.jhep.2013.05.017_b0125","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2217\/14622416.8.9.1221","article-title":"Pharmacogenetic significance of inosine triphosphatase","volume":"8","author":"Bierau","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jhep.2013.05.017_b0130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/clpt.2008.154","article-title":"Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia","volume":"85","author":"Stocco","year":"2009","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813003486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813003486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T20:28:04Z","timestamp":1539635284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827813003486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0168827813003486"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2013.05.017","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}